HEADER TRANSCRIPTION 16-MAR-18 6G05 TITLE RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-2" AND TITLE 2 RIP140 PEPTIDE AT 1.90A COMPND MOL_ID: 1; COMPND 2 MOLECULE: NUCLEAR RECEPTOR ROR-GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: C-TERMINAL DOMAIN, LIGAND BINDING DOMAIN; COMPND 5 SYNONYM: NUCLEAR RECEPTOR RZR-GAMMA,NUCLEAR RECEPTOR SUBFAMILY 1 COMPND 6 GROUP F MEMBER 3,RAR-RELATED ORPHAN RECEPTOR C,RETINOID-RELATED COMPND 7 ORPHAN RECEPTOR-GAMMA; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES; COMPND 10 MOL_ID: 2; COMPND 11 MOLECULE: NUCLEAR RECEPTOR-INTERACTING PROTEIN 1; COMPND 12 CHAIN: P, Q; COMPND 13 FRAGMENT: UNP RESIDUES 493-512; COMPND 14 SYNONYM: NUCLEAR FACTOR RIP140,RECEPTOR-INTERACTING PROTEIN 140 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: RORC, NR1F3, RORG, RZRG; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_VECTOR: PET28; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28-DERIVED VECTOR; SOURCE 11 MOL_ID: 2; SOURCE 12 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 13 ORGANISM_COMMON: HUMAN; SOURCE 14 ORGANISM_TAXID: 9606 KEYWDS FBS, NUCLEAR HORMONE RECEPTOR, LIGAND-BINDING DOMAIN, INVERSE KEYWDS 2 AGONIST, SIGNALING PROTEIN, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR J.KALLEN REVDAT 3 17-JAN-24 6G05 1 REMARK REVDAT 2 22-AUG-18 6G05 1 JRNL REVDAT 1 18-JUL-18 6G05 0 JRNL AUTH D.A.CARCACHE,A.VULPETTI,J.KALLEN,H.MATTES,D.ORAIN, JRNL AUTH 2 R.STRINGER,E.VANGREVELINGHE,R.M.WOLF,K.KAUPMANN,J.OTTL, JRNL AUTH 3 J.DAWSON,N.G.COOKE,K.HOEGENAUER,A.BILLICH,J.WAGNER, JRNL AUTH 4 C.GUNTERMANN,S.HINTERMANN JRNL TITL OPTIMIZING A WEAKLY BINDING FRAGMENT INTO A POTENT ROR GAMMA JRNL TITL 2 T INVERSE AGONIST WITH EFFICACY IN AN IN VIVO INFLAMMATION JRNL TITL 3 MODEL. JRNL REF J. MED. CHEM. V. 61 6724 2018 JRNL REFN ISSN 1520-4804 JRNL PMID 29990434 JRNL DOI 10.1021/ACS.JMEDCHEM.8B00529 REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.83 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.8 REMARK 3 NUMBER OF REFLECTIONS : 39327 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.224 REMARK 3 R VALUE (WORKING SET) : 0.223 REMARK 3 FREE R VALUE : 0.248 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2070 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4130 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 68 REMARK 3 SOLVENT ATOMS : 222 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 37.90 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 37.03 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.37000 REMARK 3 B22 (A**2) : 2.89000 REMARK 3 B33 (A**2) : -3.08000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -1.39000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.197 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.162 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.126 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 4.408 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS U VALUES : REFINED INDIVIDUALLY REMARK 4 REMARK 4 6G05 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 16-MAR-18. REMARK 100 THE DEPOSITION ID IS D_1200009209. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 22-AUG-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X10SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00000 REMARK 200 MONOCHROMATOR : SI 111 CHANNEL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : PSI PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41397 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 19.830 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.03900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.2 REMARK 200 DATA REDUNDANCY IN SHELL : 3.10 REMARK 200 R MERGE FOR SHELL (I) : 0.50700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 5NTI REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.74 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.11 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 22% PEG3350, 0.2M AMMONIUM ACETATE, REMARK 280 0.1M BIS-TRIS, PH 5.5, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 35.03950 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 860 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12540 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -9.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, P REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 890 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12400 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -8.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, Q REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 262 REMARK 465 PRO A 263 REMARK 465 GLU A 509 REMARK 465 THR A 510 REMARK 465 GLU A 511 REMARK 465 SER A 512 REMARK 465 PRO A 513 REMARK 465 VAL A 514 REMARK 465 GLY A 515 REMARK 465 LEU A 516 REMARK 465 SER A 517 REMARK 465 LYS A 518 REMARK 465 GLY B 262 REMARK 465 PRO B 263 REMARK 465 GLU B 509 REMARK 465 THR B 510 REMARK 465 GLU B 511 REMARK 465 SER B 512 REMARK 465 PRO B 513 REMARK 465 VAL B 514 REMARK 465 GLY B 515 REMARK 465 LEU B 516 REMARK 465 SER B 517 REMARK 465 LYS B 518 REMARK 465 ASN P 493 REMARK 465 SER P 494 REMARK 465 HIS P 495 REMARK 465 GLN P 496 REMARK 465 LYS P 497 REMARK 465 VAL P 498 REMARK 465 HIS P 507 REMARK 465 LYS P 508 REMARK 465 ASN P 509 REMARK 465 GLU P 510 REMARK 465 GLU P 511 REMARK 465 ASN P 512 REMARK 465 ASN Q 493 REMARK 465 SER Q 494 REMARK 465 HIS Q 495 REMARK 465 GLN Q 496 REMARK 465 LYS Q 497 REMARK 465 VAL Q 498 REMARK 465 HIS Q 507 REMARK 465 LYS Q 508 REMARK 465 ASN Q 509 REMARK 465 GLU Q 510 REMARK 465 GLU Q 511 REMARK 465 ASN Q 512 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 286 -74.17 71.70 REMARK 500 CYS A 393 56.34 -144.10 REMARK 500 GLN B 286 -64.56 74.61 REMARK 500 HIS B 458 24.31 46.94 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EF5 A 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EF5 B 601 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 6FZU RELATED DB: PDB DBREF 6G05 A 263 518 UNP P51449 RORG_HUMAN 263 518 DBREF 6G05 B 263 518 UNP P51449 RORG_HUMAN 263 518 DBREF 6G05 P 493 512 UNP P48552 NRIP1_HUMAN 493 512 DBREF 6G05 Q 493 512 UNP P48552 NRIP1_HUMAN 493 512 SEQADV 6G05 GLY A 262 UNP P51449 EXPRESSION TAG SEQADV 6G05 SER A 455 UNP P51449 CYS 455 ENGINEERED MUTATION SEQADV 6G05 GLY B 262 UNP P51449 EXPRESSION TAG SEQADV 6G05 SER B 455 UNP P51449 CYS 455 ENGINEERED MUTATION SEQRES 1 A 257 GLY PRO TYR ALA SER LEU THR GLU ILE GLU HIS LEU VAL SEQRES 2 A 257 GLN SER VAL CYS LYS SER TYR ARG GLU THR CYS GLN LEU SEQRES 3 A 257 ARG LEU GLU ASP LEU LEU ARG GLN ARG SER ASN ILE PHE SEQRES 4 A 257 SER ARG GLU GLU VAL THR GLY TYR GLN ARG LYS SER MET SEQRES 5 A 257 TRP GLU MET TRP GLU ARG CYS ALA HIS HIS LEU THR GLU SEQRES 6 A 257 ALA ILE GLN TYR VAL VAL GLU PHE ALA LYS ARG LEU SER SEQRES 7 A 257 GLY PHE MET GLU LEU CYS GLN ASN ASP GLN ILE VAL LEU SEQRES 8 A 257 LEU LYS ALA GLY ALA MET GLU VAL VAL LEU VAL ARG MET SEQRES 9 A 257 CYS ARG ALA TYR ASN ALA ASP ASN ARG THR VAL PHE PHE SEQRES 10 A 257 GLU GLY LYS TYR GLY GLY MET GLU LEU PHE ARG ALA LEU SEQRES 11 A 257 GLY CYS SER GLU LEU ILE SER SER ILE PHE ASP PHE SER SEQRES 12 A 257 HIS SER LEU SER ALA LEU HIS PHE SER GLU ASP GLU ILE SEQRES 13 A 257 ALA LEU TYR THR ALA LEU VAL LEU ILE ASN ALA HIS ARG SEQRES 14 A 257 PRO GLY LEU GLN GLU LYS ARG LYS VAL GLU GLN LEU GLN SEQRES 15 A 257 TYR ASN LEU GLU LEU ALA PHE HIS HIS HIS LEU SER LYS SEQRES 16 A 257 THR HIS ARG GLN SER ILE LEU ALA LYS LEU PRO PRO LYS SEQRES 17 A 257 GLY LYS LEU ARG SER LEU CYS SER GLN HIS VAL GLU ARG SEQRES 18 A 257 LEU GLN ILE PHE GLN HIS LEU HIS PRO ILE VAL VAL GLN SEQRES 19 A 257 ALA ALA PHE PRO PRO LEU TYR LYS GLU LEU PHE SER THR SEQRES 20 A 257 GLU THR GLU SER PRO VAL GLY LEU SER LYS SEQRES 1 B 257 GLY PRO TYR ALA SER LEU THR GLU ILE GLU HIS LEU VAL SEQRES 2 B 257 GLN SER VAL CYS LYS SER TYR ARG GLU THR CYS GLN LEU SEQRES 3 B 257 ARG LEU GLU ASP LEU LEU ARG GLN ARG SER ASN ILE PHE SEQRES 4 B 257 SER ARG GLU GLU VAL THR GLY TYR GLN ARG LYS SER MET SEQRES 5 B 257 TRP GLU MET TRP GLU ARG CYS ALA HIS HIS LEU THR GLU SEQRES 6 B 257 ALA ILE GLN TYR VAL VAL GLU PHE ALA LYS ARG LEU SER SEQRES 7 B 257 GLY PHE MET GLU LEU CYS GLN ASN ASP GLN ILE VAL LEU SEQRES 8 B 257 LEU LYS ALA GLY ALA MET GLU VAL VAL LEU VAL ARG MET SEQRES 9 B 257 CYS ARG ALA TYR ASN ALA ASP ASN ARG THR VAL PHE PHE SEQRES 10 B 257 GLU GLY LYS TYR GLY GLY MET GLU LEU PHE ARG ALA LEU SEQRES 11 B 257 GLY CYS SER GLU LEU ILE SER SER ILE PHE ASP PHE SER SEQRES 12 B 257 HIS SER LEU SER ALA LEU HIS PHE SER GLU ASP GLU ILE SEQRES 13 B 257 ALA LEU TYR THR ALA LEU VAL LEU ILE ASN ALA HIS ARG SEQRES 14 B 257 PRO GLY LEU GLN GLU LYS ARG LYS VAL GLU GLN LEU GLN SEQRES 15 B 257 TYR ASN LEU GLU LEU ALA PHE HIS HIS HIS LEU SER LYS SEQRES 16 B 257 THR HIS ARG GLN SER ILE LEU ALA LYS LEU PRO PRO LYS SEQRES 17 B 257 GLY LYS LEU ARG SER LEU CYS SER GLN HIS VAL GLU ARG SEQRES 18 B 257 LEU GLN ILE PHE GLN HIS LEU HIS PRO ILE VAL VAL GLN SEQRES 19 B 257 ALA ALA PHE PRO PRO LEU TYR LYS GLU LEU PHE SER THR SEQRES 20 B 257 GLU THR GLU SER PRO VAL GLY LEU SER LYS SEQRES 1 P 20 ASN SER HIS GLN LYS VAL THR LEU LEU GLN LEU LEU LEU SEQRES 2 P 20 GLY HIS LYS ASN GLU GLU ASN SEQRES 1 Q 20 ASN SER HIS GLN LYS VAL THR LEU LEU GLN LEU LEU LEU SEQRES 2 Q 20 GLY HIS LYS ASN GLU GLU ASN HET EF5 A 601 34 HET EF5 B 601 34 HETNAM EF5 2-(4-ETHYLSULFONYLPHENYL)-~{N}-[4-PHENYL-5- HETNAM 2 EF5 (PHENYLCARBONYL)-1,3-THIAZOL-2-YL]ETHANAMIDE FORMUL 5 EF5 2(C26 H22 N2 O4 S2) FORMUL 7 HOH *222(H2 O) HELIX 1 AA1 SER A 266 CYS A 285 1 20 HELIX 2 AA2 ARG A 288 GLN A 295 1 8 HELIX 3 AA3 ARG A 296 ASN A 298 5 3 HELIX 4 AA4 SER A 301 ARG A 310 1 10 HELIX 5 AA5 SER A 312 ARG A 337 1 26 HELIX 6 AA6 CYS A 345 MET A 365 1 21 HELIX 7 AA7 GLY A 384 GLY A 392 5 9 HELIX 8 AA8 CYS A 393 ALA A 409 1 17 HELIX 9 AA9 SER A 413 ILE A 426 1 14 HELIX 10 AB1 GLU A 435 THR A 457 1 23 HELIX 11 AB2 ARG A 459 LEU A 466 5 8 HELIX 12 AB3 GLY A 470 HIS A 490 1 21 HELIX 13 AB4 HIS A 490 PHE A 498 1 9 HELIX 14 AB5 PRO A 499 SER A 507 1 9 HELIX 15 AB6 SER B 266 GLU B 283 1 18 HELIX 16 AB7 ARG B 288 GLN B 295 1 8 HELIX 17 AB8 ARG B 296 ASN B 298 5 3 HELIX 18 AB9 SER B 301 ARG B 310 1 10 HELIX 19 AC1 SER B 312 LEU B 338 1 27 HELIX 20 AC2 CYS B 345 CYS B 366 1 22 HELIX 21 AC3 GLY B 384 GLY B 392 5 9 HELIX 22 AC4 CYS B 393 ALA B 409 1 17 HELIX 23 AC5 SER B 413 ILE B 426 1 14 HELIX 24 AC6 GLU B 435 LYS B 456 1 22 HELIX 25 AC7 THR B 457 LEU B 466 5 10 HELIX 26 AC8 PRO B 468 HIS B 490 1 23 HELIX 27 AC9 HIS B 490 PHE B 498 1 9 HELIX 28 AD1 PRO B 499 SER B 507 1 9 HELIX 29 AD2 LEU P 500 GLY P 506 1 7 HELIX 30 AD3 LEU Q 500 GLY Q 506 1 7 SHEET 1 AA1 3 TYR A 369 ASN A 370 0 SHEET 2 AA1 3 THR A 375 PHE A 378 -1 O THR A 375 N ASN A 370 SHEET 3 AA1 3 LYS A 381 GLY A 383 -1 O LYS A 381 N PHE A 378 SHEET 1 AA2 3 TYR B 369 ASN B 370 0 SHEET 2 AA2 3 THR B 375 PHE B 378 -1 O THR B 375 N ASN B 370 SHEET 3 AA2 3 LYS B 381 GLY B 383 -1 O LYS B 381 N PHE B 378 SITE 1 AC1 17 CYS A 285 GLN A 286 LEU A 287 CYS A 320 SITE 2 AC1 17 HIS A 323 LEU A 324 ARG A 364 MET A 365 SITE 3 AC1 17 ARG A 367 ALA A 368 PHE A 377 PHE A 378 SITE 4 AC1 17 PHE A 388 ILE A 400 PHE A 401 HOH A 710 SITE 5 AC1 17 HOH A 749 SITE 1 AC2 17 CYS B 285 GLN B 286 LEU B 287 CYS B 320 SITE 2 AC2 17 HIS B 323 LEU B 324 ARG B 364 MET B 365 SITE 3 AC2 17 ARG B 367 ALA B 368 PHE B 377 PHE B 378 SITE 4 AC2 17 PHE B 388 ILE B 400 PHE B 401 HOH B 708 SITE 5 AC2 17 HOH B 741 CRYST1 48.092 70.079 81.996 90.00 101.58 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020793 0.000000 0.004259 0.00000 SCALE2 0.000000 0.014270 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012449 0.00000